📗 Cite This Artifact
Lysosomal Enzyme Dysfunction Across Neurodegenerative Diseases
Lysosomal Enzyme Dysfunction Across Neurodegenerative Diseases: A Comparative Analysis
Overview
Lysosomal dysfunction has emerged as a unifying pathological mechanism across multiple neurodegenerative diseases. While each disease has distinct primary protein pathologies, converging evidence demonstrates that impaired lysosomal enzyme activity represents a shared downstream pathway driving neuronal death[@nixon2024][@root2022].
This comparison examines how specific lysosomal enzymes — including cathepsins, glucocerebrosidase (GBA/GCase), acid alpha-glucosidase (GAA), and other hydrolases — contribute to disease pathogenesis across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).
Lysosomal Enzyme Reference Table
...
Lysosomal Enzyme Dysfunction Across Neurodegenerative Diseases: A Comparative Analysis
Overview
Lysosomal dysfunction has emerged as a unifying pathological mechanism across multiple neurodegenerative diseases. While each disease has distinct primary protein pathologies, converging evidence demonstrates that impaired lysosomal enzyme activity represents a shared downstream pathway driving neuronal death[@nixon2024][@root2022].
This comparison examines how specific lysosomal enzymes — including cathepsins, glucocerebrosidase (GBA/GCase), acid alpha-glucosidase (GAA), and other hydrolases — contribute to disease pathogenesis across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).
Lysosomal Enzyme Reference Table
| Enzyme | Gene | Function | AD | PD | ALS | FTD | HD | Key Reference |
|--------|------|----------|----|----|-----|-----|----|----|
| Cathepsin D | CTSD | Aspartyl protease; degrades Aβ, α-syn, tau | Deficient | Impaired | ↓ | Dysregulated | ↓ | [@bobe2019] |
| Cathepsin B | CTSB | Cysteine protease; hydrolyzes peptides | Elevated | Imbalanced | Altered | Imbalanced | Altered | [@nixon2024] |
| Cathepsin L | CTSL | Cysteine protease; protein turnover | Impaired | ↓ | Altered | Altered | ↓ | [@root2022] |
| Cathepsin S | CTSS | Cysteine protease; immune regulation | ↑ in microglia | Implicated | Unknown | Unknown | Unknown | [@lie2019] |
| Cathepsin A | CTSA | Serine protease; ganglioside metabolism | Implicated | Implicated | Unknown | Unknown | Unknown | [@nixon2024] |
| Glucocerebrosidase (GCase) | GBA1 | Cleaves glucosylceramide → glucose + ceramide | Reduced activity | Mutations ↑ risk 5–20× | Not primary | Not primary | Not primary | [@zhang2024] |
| Acid alpha-glucosidase (GAA) | GAA | Cleaves glycogen in lysosomes | Implicated | Not primary | Not primary | Not primary | Not primary | [@nixon2024] |
| Arylsulfatase A | ARSA | Cleaves sulfatides | Implicated | Not primary | Not primary | Not primary | Implicated (MLD) | [@lie2019] |
| Hexosaminidase A | HEXA | Cleaves GM2 gangliosides | Implicated (Tay-Sachs models) | Not primary | Not primary | Not primary | Not primary | [@nixon2024] |
| ATP13A2 (PARK9) | ATP13A2 | Lysosomal P5-type ATPase; polyamine transport | Impaired | Mutations → Kufor-Rakeb | Implicated | Implicated | Implicated | [@ren2022] |
| NPC1 | NPC1 | Cholesterol trafficking | Impaired | Not primary | Not primary | Not primary | Not primary (NPC2) | [@lie2019] |
| LAMP2 | LAMP2 | Lysosomal membrane protein; autophagy | Altered | Implicated (Danon) | Impaired | Impaired | Impaired | [@root2022] |
Pathological Mechanisms Comparison
Disease-Specific Mechanisms
Alzheimer's Disease
Lysosomal dysfunction in AD manifests through multiple interconnected pathways[@ad_lysosomal]. The accumulation of Aβ peptides within lysosomes causes lysosomal membrane permeabilization (LMP), leading to release of hydrolytic enzymes into the cytoplasm. Cathepsins B and D are elevated in AD brain tissue and contribute to tau hyperphosphorylation through activation of various kinases.
Key enzymes affected in AD:
- Cathepsin D: Deficient activity leads to impaired Aβ degradation and accumulation. Upregulated in early AD but becomes dysfunctional with age[@bobe2019].
- Cathepsin B: Elevated in reactive microglia; can contribute to inflammasome activation and neurotoxicity when released extracellularly.
- GBA/GCase: Reduced activity has been reported in AD brains, contributing to glucosylceramide accumulation and impaired autophagy.
- LAMP2: Altered expression in AD neurons affects chaperone-mediated autophagy (CMA).
Autophagy impairment results in accumulation of autophagic vacuoles within neurons, particularly in the hippocampus and cortex. The TREM2 variant (R47H) impairs microglial phagocytosis, reducing clearance of Aβ and increasing lysosomal stress.
Parkinson's Disease
PD demonstrates perhaps the strongest link between lysosomal enzyme dysfunction and disease pathogenesis[@pd_lysosomal]. Heterozygous GBA1 mutations (N370S, L444P, 84GG, RecNcil) are the most significant genetic risk factor for sporadic PD, increasing risk 5–20-fold depending on the specific variant[@zhang2024].
Key enzymes affected in PD:
- GBA/GCase: The strongest genetic link to PD. GCase deficiency leads to glucosylceramide accumulation, which directly promotes α-synuclein aggregation. The relationship is bidirectional — α-synuclein oligomers further inhibit GCase trafficking and function[@zhang2024].
- ATP13A2 (PARK9): Mutations cause Kufor-Rakeb syndrome, a juvenile-onset parkinsonism. ATP13A2 maintains lysosomal pH, transports polyamines, and its loss causes cathepsin D deficiency and α-synuclein accumulation.
- LRRK2: While not a lysosomal enzyme per se, LRRK2 mutations (G2019S, R1441G/C) disrupt lysosomal trafficking by hyperphosphorylating Rab GTPases. LRRK2 is recruited to damaged lysosomes via Rab29/Rab7L1, and its kinase activity suppresses TFEB nuclear translocation[@pd_lysosomal][@kauffman2024].
- Cathepsin D: Altered activity in PD substantia nigra; contributes to dopaminergic neuron vulnerability.
Autophagy-lysosomal pathway impairment leads to accumulation of damaged mitochondria and α-synuclein oligomers. TFEB nuclear translocation is impaired in both sporadic and GBA-related PD[@kauffman2024].
Amyotrophic Lateral Sclerosis
ALS features prominent autophagy-lysosomal pathway dysfunction with multiple lysosomal enzymes affected[@als_lysosomal]. TDP-43 aggregates impair autophagy initiation through multiple mechanisms, including mTORC1 dysregulation and transcription factor inhibition.
Key enzymes affected in ALS:
- Cathepsin D: Altered activity in motor neurons; deficiency contributes to impaired protein clearance.
- Cathepsin A: Implicated in ganglioside metabolism relevant to motor neuron membranes.
- LAMP2: Mutations cause Danon disease (autophagy-lysosomal dysfunction cardiomyopathy with ALS-like features).
- GCase: Not primarily involved in ALS, but lysosomal lipid metabolism is generally impaired.
Mutations in autophagy receptors (SQSTM1/p62, OPTN, TBK1) directly impair autophagosome formation and lysosomal fusion. SOD1 mutations cause lysosomal membrane damage and cathepsin release. Mitophagy is particularly affected due to defects in PINK1/PARKIN signaling and OPTN function. C9orf72 hexanucleotide expansions cause autophagy dysregulation through multiple pathways.
Frontotemporal Dementia
FTD, particularly the GRN subtype, demonstrates direct lysosomal dysfunction as a primary disease mechanism[@ftd_lysosomal]. Progranulin (encoded by GRN) is a lysosomal enzyme that regulates cathepsin activity and lipid metabolism. GRN haploinsufficiency leads to cathepsin D and L dysregulation, resulting in TDP-43 pathology.
Key enzymes affected in FTD:
- Cathepsin D: Directly dysregulated by progranulin deficiency; elevated activity contributes to neuronal death in GRN-FTD.
- Cathepsin L: Imbalanced in progranulin-deficient neurons; contributes to proteostasis failure.
- LAMP2: Altered in FTD neurons; affects chaperone-mediated autophagy.
- GBA/GCase: GBA variants modify risk and phenotype in GRN-FTD.
TMEM106b variants modulate progranulin levels and lysosomal function. Lysosomal dysfunction in FTD leads to lipofuscin accumulation and impaired protein clearance. Some FTD cases show overlap with ALS (FTD-ALS spectrum), sharing lysosomal mechanisms. Complete loss of progranulin causes neuronal ceroid lipofuscinosis, directly linking FTD to lysosomal storage disorders.
Huntington's Disease
HD demonstrates autophagy impairment at multiple levels involving lysosomal enzymes[@hd_lysosomal]. Mutant huntingtin (mHTT) interacts with autophagy receptors (p62, NBR1), impairing cargo recognition and selective autophagy.
Key enzymes affected in HD:
- Cathepsin D: Altered activity in HD striatum; contributes to impaired autophagosome-lysosome fusion.
- Cathepsin B: Elevated in HD models; may contribute to inflammatory activation.
- GBA/GCase: Not a primary HD mechanism, but lipid dysregulation is prominent.
mHTT also disrupts lysosomal function by altering cathepsin activity and membrane trafficking. Impaired mitophagy leads to accumulation of dysfunctional mitochondria. The autophagy block prevents clearance of mHTT aggregates, creating a vicious cycle. Autophagy enhancers (rapamycin, trehalose) have shown promise in preclinical models.
Clinical Trials Targeting Lysosomal Enzymes
| Trial | Phase | Disease | Target Enzyme | Intervention | Status | NCT |
|-------|-------|---------|--------------|--------------|--------|-----|
| Ambroxol PD Progression | Phase III | PD | GCase | Pharmacological chaperone | Recruiting | NCT05778617 |
| Ambroxol ASPro-PD | Phase 2/3 | PD | GCase | Pharmacological chaperone | Active | NCT05827068 |
| BIA 28-6156 | Phase 2 | PD (GBA+) | GCase | Small molecule chaperone | Recruiting | NCT05819359 |
| MRgFUS + GCase | Phase 1 | PD | GCase | Focused ultrasound + enzyme replacement | Recruiting | NCT05565443 |
| BIIB122 (LUMA) LRRK2i | Phase 2b | PD | LRRK2 (lysosomal trafficking) | LRRK2 kinase inhibitor | Active, not recruiting | NCT05348785 |
| Venglustat | Phase 2 | PD (GBA+) | GCase (substrate reduction) | Glucosylceramide synthase inhibitor | Stopped | NCT02947156 |
| AT3375 | Phase 1 | PD (GBA+) | GCase | Pharmacological chaperone | Phase 1 | — |
| LTI-291 | Phase 1 | PD | GCase activator | GCase activator | Phase 1 | — |
Key Trial Details
Ambroxol (NCT05778617): UCL-sponsored 330-participant Phase IIIa placebo-controlled trial, 104-week treatment duration. Primary endpoint: change in MDS-UPDRS Parts I–III. 12-month interim results showed sustained GCase activity increase and acceptable safety profile[@pd_gba_clinical].
BIA 28-6156 (NCT05819359): Bial Pharmaceutical Phase 2 trial specifically targeting GBA-mutation carriers with a novel oral small molecule GCase chaperone. Dose escalation with biomarker endpoints.
LUMA (NCT05348785): Biogen/Denali Phase 2b trial of BIIB122 (DNL151), a LRRK2 kinase inhibitor. 650 participants, primary endpoint time-to-confirmed worsening in MDS-UPDRS. LRRK2 inhibition restores normal lysosomal trafficking and TFEB activation.
Shared Therapeutic Targets
| Target | Rationale | Therapeutic Approach | Clinical Stage |
|--------|-----------|---------------------|----------------|
| GBA/GCase | Restore enzyme activity, reduce glucosylceramide | Pharmacological chaperones (ambroxol, BIA 28-6156), gene therapy, substrate reduction | Phase 2/3 |
| Cathepsin D | Restore proteolytic balance | Small molecule modulators | Preclinical |
| TFEB activation | Promote lysosomal biogenesis | mTORC1 inhibitors, HDAC inhibitors, small molecule activators | Preclinical/clinical |
| V-ATPase | Restore lysosomal acidification | Small molecules, acidic nanoparticles | Preclinical |
| LAMP2 | Restore autophagy-lysosome fusion | Gene therapy, small molecule enhancers | Preclinical |
| ATP13A2 | Restore polyamine transport and pH | Gene therapy, small molecules | Preclinical |
| mTORC1 | De-repress autophagy initiation | Rapamycin, active-site inhibitors | Preclinical |
| Autophagy receptors | Enhance selective autophagy | TBK1 inhibitors, p62 modulators | Preclinical |
Lysosomal Storage Disease Overlap with Neurodegeneration
Several lysosomal storage diseases (LSDs) share pathological features with sporadic neurodegenerative diseases, providing insights into common mechanisms:
Gaucher Disease (GBA mutations): The most common LSD, caused by glucocerebrosidase deficiency. GBA mutations are the strongest genetic risk factor for PD (5-20x increased risk). Accumulation of glucosylceramide and glucosylsphingosine occurs. Parkinsonism develops in 5-10% of Gaucher patients, often before age 40.
Niemann-Pick Disease Type C: Involves cholesterol trafficking defects. NPC1 mutations associated with some AD cases. Lysosomal calcium dysregulation common to both NPC and neurodegeneration.
Farber Disease: Ceramide accumulation causes neurodegeneration, demonstrating the role of lipid metabolism in neuronal survival.
Common pathogenic mechanisms shared between LSDs and neurodegeneration:
Lysosomal Enzyme Activity Measurement
| Enzyme | Normal Activity | Disease States | Measurement Method |
|--------|-----------------|----------------|-------------------|
| Cathepsin D | 100% baseline | AD: 40-60%, PD: 60-80% | Fluorometric assay |
| GCase (glucocerebrosidase) | 100% baseline | PD (GBA): 30-50% | Colorimetric |
| Cathepsin B | 100% baseline | AD: 50-70% | Fluorometric |
| Hexosaminidase | 100% baseline | Various LSDs | Colorimetric |
Clinical Biomarkers for Lysosomal Function
| Biomarker | Method | Disease Relevance |
|-----------|--------|-------------------|
| Cathepsin D activity | CSF enzymatic assay | AD, PD, FTD |
| GCase activity | Blood/Lyso-Gb1 | PD with GBA mutations |
| LAMP-1 | CSF ELISA | General lysosomal dysfunction |
| Autophagy markers (p62, LC3) | Blood Western blot | Monitoring autophagy induction |
| Lyso-Gb1 (glucosylsphingosine) | Blood | Sensitive for GBA carriers, correlates with PD risk |
Cross-References
Related Diseases
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Cathepsin deficiency and Aβ accumulation
- [Parkinson's Disease](/diseases/parkinsons-disease) — GBA mutations, α-synuclein, LRRK2
- [Amyotrophic Lateral Sclerosis](/diseases/als) — TDP-43, autophagy block, C9orf72
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia) — GRN, progranulin, cathepsin D
- [Huntington's Disease](/diseases/huntingtons-disease) — mHTT, autophagy receptors, cathepsin D
Related Mechanisms
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway) — Core degradation pathway
- [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders) — Direct enzyme deficiency models
- [Mitochondrial Quality Control](/mechanisms/mitochondrial-quality-control) — Mitophagy connection
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway) — Lysosomal-immune axis
Related Genes
- [GBA](/genes/gba) — PD risk gene, glucocerebrosidase
- [LRRK2](/genes/lrrk2) — Lysosomal trafficking regulator
- [TREM2](/genes/trem2) — Microglial lysosomal signaling
- [GRN](/genes/grn) — Progranulin, lysosomal enzyme regulator
- [C9orf72](/genes/c9orf72) — Autophagy-lysosomal dysregulation
- [ATP13A2](/genes/atp13a2) — Lysosomal P5-type ATPase
Related Proteins
- [Glucocerebrosidase (GCase)](/proteins/gba-protein) — GBA enzyme
- [Cathepsin D](/proteins/cathepsin-d) — Key aspartyl protease
- [Cathepsin B](/proteins/cathepsin-b) — Cysteine protease
- [Alpha-Synuclein](/proteins/alpha-synuclein) — Lysosomal clearance substrate
Related Therapeutics
- [Ambroxol for Parkinson's](/therapeutics/ambroxol-parkinsons) — GCase chaperone
- [LRRK2-GBA Combination Therapy](/therapeutics/lrrk2-gba-combination-therapy) — Dual targeting
- [ATP13A2 Therapy for Parkinson's](/therapeutics/atp13a2-therapy-parkinsons) — ATP13A2 targeting
- [Pharmacological Chaperones](/therapeutics/proteostasis-therapy) — Enzyme stabilization
Related Clinical Trials
- [Ambroxol to Slow Progression in Parkinson Disease (NCT05778617)](/clinical-trials/ambroxol-parkinson-progression-nct05778617)
- [Ambroxol ASPro-PD Trial (NCT05827068)](/clinical-trials/ambroxol-aspro-pd)
- [BIA 28-6156 for GBA-Parkinson's Disease](/clinical-trials/bia-28-6156-gba-parkinsons)
- [BIIB122 (LUMA) LRRK2 Inhibitor Trial](/clinical-trials/biib122-luma-lrrk2-inhibitor-pd)
- [NCT05565443: MR-Guided Focused Ultrasound + GCase for PD](/clinical-trials/mr-guided-focused-ultrasound-gcase-pd)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | diseases-lysosomal-dysfunction-neurodegeneration-comparison |
| kg_node_id | None |
| entity_type | disease |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-c9bf82f2de62 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-lysosomal-dysfunction-neurodegeneration-comparison'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-diseases-lysosomal-dysfunction-neurodegeneration-comparison?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Lysosomal Enzyme Dysfunction Across Neurodegenerative Diseases](http://scidex.ai/artifact/wiki-diseases-lysosomal-dysfunction-neurodegeneration-comparison)
http://scidex.ai/artifact/wiki-diseases-lysosomal-dysfunction-neurodegeneration-comparison